Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while ProShares UltraPro Short QQQ ETF trades at $32.7 (market cap $2.23B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 34.1× ProShares UltraPro Short QQQ ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| REGN | SQQQ | |
|---|---|---|
Market Cap | $76.14B | $2.23B |
Volume | 500,239 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $89.43 |
52-Week Low | $557.73 | $31.83 |
Typical Hold Time | 107 Days | 12 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
SQQQ (ProShares UltraPro Short QQQ) trades at $32.08, up 0.79% today, as a 3x leveraged inverse ETF designed to profit from declines in the Nasdaq-100. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential near-term oversold conditions. The ETF serves as a hedging tool against tech sector weakness, with recent news highlighting its strategic use alongside long QQQ positions.
Outlook remains tied to Nasdaq-100 performance; further tech sector declines could benefit SQQQ, but leveraged decay and volatility pose significant risks. Investors using SQQQ for hedging should monitor market sentiment and sector-specific catalysts. The ETF's structure makes it unsuitable for long-term holdings due to compounding effects in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
